Covaxin Bharat Biotech
- All
- News
- Videos
-
Top Medical Body Slams Study On Covaxin Safety, Side-Effects, Wants Apology
The Indian Council of Medical Research, or ICMR, has distanced itself from a follow-up study by two Banaras Hindu University professors that said nearly a third of 926 individuals who got the India-made Covaxin shot reported serious side-effects.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
50 Million Doses Of Covaxin Set To Expire Early 2023: Report
Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.
-
Japan Approves Covaxin Booster Dose For Travellers: Bharat Biotech
Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Covaxin Maker Gets $19 Million For Development Of 'Variant Proof' Vaccine
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.
-
"Portrays Incorrect Picture": Government On Reports Of Covaxin Concern
Centre said that reports apparently quoting a communication from the MEA asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval nod for its COVID jab, "potrayed an incorrect picture."
-
"Bharat Biotech Must Address WHO's Covaxin Suspension To Avoid...": Centre
Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world health body's emergency use approval for the jab.
-
Covaxin Cleared For 6-12 Age Group, Corbevax For 5-12-Year-Olds
The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.
-
No Doubts On Safety, Efficacy: WHO Chief Scientist On Covaxin Suspension
Soumya Swaminathan, Chief Scientist at the World Health Organisation, today assured that the freeze on Bharat Biotech's Covaxin supply does not involve the safety or efficacy of the vaccine, but some issues in manufacturing processes for which correc
-
Top Medical Body Slams Study On Covaxin Safety, Side-Effects, Wants Apology
The Indian Council of Medical Research, or ICMR, has distanced itself from a follow-up study by two Banaras Hindu University professors that said nearly a third of 926 individuals who got the India-made Covaxin shot reported serious side-effects.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
50 Million Doses Of Covaxin Set To Expire Early 2023: Report
Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.
-
Japan Approves Covaxin Booster Dose For Travellers: Bharat Biotech
Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Covaxin Maker Gets $19 Million For Development Of 'Variant Proof' Vaccine
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.
-
"Portrays Incorrect Picture": Government On Reports Of Covaxin Concern
Centre said that reports apparently quoting a communication from the MEA asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval nod for its COVID jab, "potrayed an incorrect picture."
-
"Bharat Biotech Must Address WHO's Covaxin Suspension To Avoid...": Centre
Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world health body's emergency use approval for the jab.
-
Covaxin Cleared For 6-12 Age Group, Corbevax For 5-12-Year-Olds
The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.
-
No Doubts On Safety, Efficacy: WHO Chief Scientist On Covaxin Suspension
Soumya Swaminathan, Chief Scientist at the World Health Organisation, today assured that the freeze on Bharat Biotech's Covaxin supply does not involve the safety or efficacy of the vaccine, but some issues in manufacturing processes for which correc
-
1:20